<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607760</url>
  </required_header>
  <id_info>
    <org_study_id>ECMO</org_study_id>
    <nct_id>NCT03607760</nct_id>
  </id_info>
  <brief_title>Extracorporeal Membrane Oxygenation (ECMO)</brief_title>
  <official_title>Extracorporeal Membrane Oxygenation (ECMO) and Neonatal Outcomes:a Retrospective Multicenters Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayi Children's Hospital Affiliated to PLA Army General Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the general navy hospital of the PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhengzhou Children's Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou Women and Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the 1970s, extracorporeal membrane oxygenation (ECMO) support has been used to support
      gas exchange for children with severe acute respiratory failure who fail mechanical
      ventilation. ECMO is more expensive than each of these other procedures.But its action is
      unclear
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Since 1974, eight randomized controlled trials have been reported in ECMO for respiratory
      failure, and none have included non-neonatal pediatric patients. Cochrane systematic reviews
      of this evidence concluded that ECMO for neonatal respiratory failure had a survival
      advantage, but there was insufficient evidence to demonstrate a survival advantage for ECMO
      used to support respiratory failure in adults. Moreover, these trials were performed prior to
      2009, and since then advances in ECMO technology have enhanced the delivery of ECMO support,
      and new research has changed conventional management of severe acute respiratory distress
      syndrome (ARDS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>in-hospital mortality</measure>
    <time_frame>36 weeks' gestational age or before discharge from hospital</time_frame>
    <description>the patients died</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28 days' mortality</measure>
    <time_frame>28 days</time_frame>
    <description>the patients died</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal necrotizing enterocolitis</measure>
    <time_frame>36 weeks' gestational age or before discharge from hospital</time_frame>
    <description>Neonatal necrotizing enterocolitis was diagnosed after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraventricular hemorrhage</measure>
    <time_frame>36 weeks' gestational age or before discharge from hospital</time_frame>
    <description>Intraventricular hemorrhage was diagnosed after extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bronchopulmonary dysplasia</measure>
    <time_frame>36 weeks' gestational age or before discharge from hospital</time_frame>
    <description>bronchopulmonary dysplasia was diagnosed after extubation</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Extracorporeal Membrane Oxygenation</condition>
  <arm_group>
    <arm_group_label>ECMO</arm_group_label>
    <description>severe respiratory failure with ECMO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional mechanical ventilation</arm_group_label>
    <description>severe respiratory failure with conventional mechanical ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECMO</intervention_name>
    <description>the patients with severe respiratory failure were supported by ECMO</description>
    <arm_group_label>ECMO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>conventional mechanical ventilation</intervention_name>
    <description>the patients with severe respiratory failure were supported by conventional mechanical ventilation</description>
    <arm_group_label>conventional mechanical ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients will be eligible only when they reach the cutting line in the following:

        Gestational age &gt; 36 weeks, birth weight &gt; 2 kg, day post-birth &lt; 28 days.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. ECMO group:

          1. Oxygenation Index &gt; 40 for &gt;4 hours

          2. Failure to wean from 100% oxygen despite prolonged (&gt; 48h) maximal medical therapy or
             persistent episodes of decompensation

          3. Severe hypoxic respiratory failure with acute decompensation (PaO2 &lt;40) unresponsive
             to intervention

          4. Severe pulmonary hypertension with evidence of right ventricular dysfunction and/or
             left ventricular dysfunction. The pulmonary artery pressure &gt; 60mmHg evaluated by the
             Echo, arterial duct keeps open and the blood flow was either by-level shunt or
             completely shunt from right side to left side.

        2. Non-ECMO group:

          1. Oxygenation Index &gt; 16 and reach the Montreux definition of severe respiratory
             distress syndrome

          2. Vasoactive-inotropic score (VIS) ≥ 40 [VIS=dopamine dose (μg/kg/min)×1 + dobutamine
             dose (μg/kg/min)×1 + milrinone dose (μg/kg/min)×10 + amrinone dose (μg/kg/min)×10 +
             epinephrine dose (μg/kg/min)×100 + isoprenaline dose (μg/kg/min)×100]

        Exclusion Criteria:

          1. Gestational age &lt; 36 weeks, birth weight &lt; 2 kg, day post-birth &gt; 28 days.

          2. lethal chromosomal disorder (includes trisomy 13, 18 but not 21) or any other lethal
             anomaly

          3. irreversible brain damage

          4. uncontrolled bleeding

          5. Grade III or greater intraventricular hemorrhage

          6. ventilator days ≥ 15 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Chen Long,MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

